The enrollment completion removes a key timeline risk, but the stock remains binary on trial results due in ~1 year. Monitor for any interim analyses or regulatory updates. Short-term traders may see a small pop on the news, but long-term holders should wait for top-line data before adding to positions.
Price Chart
Executive Summary
Mesoblast announced completion of enrollment (at least 300 patients) in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. This milestone de-risks the trial timeline, but results are not expected until mid-2027, leaving significant binary risk. The stock may see a modest positive reaction, but the lack of efficacy data limits the near-term catalyst.
Key Facts
- Enrollment target of at least 300 patients achieved in MSB-DR004 Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease.
- Top-line results expected in mid-CY2027 after the last patient completes 12 months follow-up.
- Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, providing eligibility for priority review and rolling BLA review.
- Company estimates peak year revenue potential of >$10 billion with single-digit market penetration, though this is forward-looking and not supported by current data.
Financial Impact
No financial data in this press release. Potential peak revenue >$10B cited by company, but this is a forward-looking estimate and not a hard financial figure.
Risk Factors
- Trial may fail to meet primary endpoint, leading to significant downside.
- Regulatory delays or CMC issues could push BLA filing and approval timeline.
- Competing therapies or changes in standard of care could reduce commercial potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326541 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.07 (−15.41%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.07 (−17.30%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.07 (−3.26%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.07 (−0.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access